These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
480 related articles for article (PubMed ID: 34687672)
1. Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients. Giacomelli C; Piccarducci R; Marchetti L; Romei C; Martini C Biochem Pharmacol; 2021 Nov; 193():114812. PubMed ID: 34687672 [TBL] [Abstract][Full Text] [Related]
2. Pulmonary fibrosis in COVID-19: mechanisms, consequences and targets. O'Reilly S QJM; 2023 Oct; 116(9):750-754. PubMed ID: 37191984 [TBL] [Abstract][Full Text] [Related]
3. [Pulmonary fibrosis in patients with COVID-19: A review]. Chuchalin AG Ter Arkh; 2022 Dec; 94(11):1333-1339. PubMed ID: 37167174 [TBL] [Abstract][Full Text] [Related]
4. Cellular and Molecular Mechanism of Pulmonary Fibrosis Post-COVID-19: Focus on Galectin-1, -3, -8, -9. Oatis D; Simon-Repolski E; Balta C; Mihu A; Pieretti G; Alfano R; Peluso L; Trotta MC; D'Amico M; Hermenean A Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897786 [TBL] [Abstract][Full Text] [Related]
6. Involvement of the ACE2/Ang-(1-7)/MasR Axis in Pulmonary Fibrosis: Implications for COVID-19. Morganstein T; Haidar Z; Trivlidis J; Azuelos I; Huang MJ; Eidelman DH; Baglole CJ Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884756 [TBL] [Abstract][Full Text] [Related]
7. Association of COVID-19 and other viral infections with interstitial lung diseases, pulmonary fibrosis, and pulmonary hypertension: A narrative review. Atabati E; Dehghani-Samani A; Mortazavimoghaddam SG Can J Respir Ther; 2020; 56():1-9. PubMed ID: 33274259 [TBL] [Abstract][Full Text] [Related]
8. Potential mechanisms for lung fibrosis associated with COVID-19 infection. Parimon T; Espindola M; Marchevsky A; Rampolla R; Chen P; Hogaboam CM QJM; 2023 Jul; 116(7):487-492. PubMed ID: 36018274 [TBL] [Abstract][Full Text] [Related]
9. Effectivity of mesenchymal stem cells for bleomycin-induced pulmonary fibrosis: a systematic review and implication for clinical application. Zhao Y; Yan Z; Liu Y; Zhang Y; Shi J; Li J; Ji F Stem Cell Res Ther; 2021 Aug; 12(1):470. PubMed ID: 34420515 [TBL] [Abstract][Full Text] [Related]
10. Lung recovery with prolonged ECMO following fibrotic COVID-19 acute respiratory distress syndrome. Kazi AW; Summer R; Sundaram B; George G Am J Med Sci; 2023 Mar; 365(3):307-312. PubMed ID: 36535539 [TBL] [Abstract][Full Text] [Related]
11. Recent Findings on Cell-Based Therapies for COVID19-Related Pulmonary Fibrosis. Chuang HM; Ho LI; Harn HJ; Liu CA Cell Transplant; 2021; 30():963689721996217. PubMed ID: 33845643 [TBL] [Abstract][Full Text] [Related]
13. Pulmonary fibrosis: A short- or long-term sequelae of severe COVID-19? Zheng Z; Peng F; Zhou Y Chin Med J Pulm Crit Care Med; 2023 Jun; 1(2):77-83. PubMed ID: 37388822 [TBL] [Abstract][Full Text] [Related]
14. Can biomarkers of extracellular matrix remodelling and wound healing be used to identify high risk patients infected with SARS-CoV-2?: lessons learned from pulmonary fibrosis. Leeming DJ; Genovese F; Sand JMB; Rasmussen DGK; Christiansen C; Jenkins G; Maher TM; Vestbo J; Karsdal MA Respir Res; 2021 Feb; 22(1):38. PubMed ID: 33546680 [TBL] [Abstract][Full Text] [Related]
15. Human-Based Advanced Kiener M; Roldan N; Machahua C; Sengupta A; Geiser T; Guenat OT; Funke-Chambour M; Hobi N; Kruithof-de Julio M Front Med (Lausanne); 2021; 8():644678. PubMed ID: 34026781 [TBL] [Abstract][Full Text] [Related]
16. COVID-19 and interstitial lung diseases: A multifaceted look at the relationship between the two diseases. Fukihara J; Kondoh Y Respir Investig; 2023 Sep; 61(5):601-617. PubMed ID: 37429073 [TBL] [Abstract][Full Text] [Related]
17. Healing after COVID-19: are survivors at risk for pulmonary fibrosis? McDonald LT Am J Physiol Lung Cell Mol Physiol; 2021 Feb; 320(2):L257-L265. PubMed ID: 33355522 [TBL] [Abstract][Full Text] [Related]
18. [COVID-19 and autoimmune dysregulation: exploring common mechanisms and treatment strategies in interstitial lung disease]. Zhang Z; Zhou M Zhonghua Jie He He Hu Xi Za Zhi; 2024 Jun; 47(6):571-575. PubMed ID: 38858210 [TBL] [Abstract][Full Text] [Related]
19. Proteomics of severe SARS-COV-2 infection and paraquat poisoning in human lung tissue samples: comparison of microbial infected and toxic pulmonary fibrosis. Min J; Jiaqi H; Lihua L; Qianqian C; Shujuan W; Xiang L; Liang L; Liang R; Yiwu Z; Qian L Front Cell Infect Microbiol; 2024; 14():1446305. PubMed ID: 39301288 [TBL] [Abstract][Full Text] [Related]
20. Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host Mediators. O'Hare M; Amarnani D; Whitmore HAB; An M; Marino C; Ramos L; Delgado-Tirado S; Hu X; Chmielewska N; Chandrahas A; Fitzek A; Heinrich F; Steurer S; Ondruschka B; Glatzel M; Krasemann S; Sepulveda-Falla D; Lagares D; Pedron J; Bushweller JH; Liu P; Arboleda-Velasquez JF; Kim LA Am J Pathol; 2021 Jul; 191(7):1193-1208. PubMed ID: 33894177 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]